Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cystic Fibrosis: Implications for Vascular Health and Function

NCT07904325 is registered in ClinicalTrials.gov with Liverpool Heart and Chest Hospital NHS Foundation Trust as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07904325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Cystic Fibrosis: Implications for Vascular Health and Function
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Phase
Observational
Overall status
Not yet recruiting
Start date
October 10, 2026
Completion date
July 1, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular risk factor, cystic fibrosis, endothelial dysfunction

Arms

As registered; 2 arms.

  • Adults with cystic fibrosis Non-invasive vascular, cerebrovascular and autonomic assessment

    Adults aged 40 years or older with a confirmed diagnosis of cystic fibrosis, receiving CFTR modulator therapy at a recognised therapeutic dose and clinically stable (no pulmonary exacerbation or hospitalisation in the previous 4 weeks), recruited consecutively from the adult CF outpatient clinics at Liverpool Heart and Chest Hospital. Target n = 50. Participants attend a single study visit for vascular, cerebrovascular, autonomic, blood, cognitive and questionnaire assessments.

  • Healthy controls Non-invasive vascular, cerebrovascular and autonomic assessment

    Healthy adults aged 40 years or older, matched to participants with CF for sex and age (within 4 years), in sinus rhythm with normal blood pressure (below 140/90 mmHg) and taking no prescription medications other than contraceptives or hormone replacement therapy. Recruited from the local community (including NHS and university staff and students) via advertisements. Target n = 50. Participants attend a single study visit at Liverpool Heart and Chest Hospital or Manchester Metropolitan University for the same assessments as the CF group.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Radial artery flow-mediated dilation (FMD) Single study visit (Day 1)

    Percentage change in radial artery diameter

  • Radial artery low-flow mediated constriction (L-FMC) Single study visit (Day 1)

    Percentage change in radial artery diameter

Lead sponsor's other trials

Liverpool Heart and Chest Hospital NHS Foundation Trust, most recent start first.

Similar trials

Same condition (Cystic Fibrosis) and phase, most recent start first.